Cargando…

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

BACKGROUND: Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. METHODS: ER-positive early breast cancer patients operated at Ruijin Hosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shuai, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Chen, Xiaosong, Shen, Kunwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278709/ https://www.ncbi.nlm.nih.gov/pubmed/34256710 http://dx.doi.org/10.1186/s12885-021-08555-4

Ejemplares similares

HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
por: Li, Shuai, et al.
Publicado: (2020)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
por: Hong, Jin, et al.
Publicado: (2019)

IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2020)

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age
por: Yu, Jing, et al.
Publicado: (2021)

Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study
por: Zong, Yu, et al.
Publicado: (2014)

A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer
por: Lin, Caijin, et al.
Publicado: (2020)

Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
por: Fang, Yan, et al.
Publicado: (2020)

Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
por: Lu, Yujie, et al.
Publicado: (2023)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
por: Wu, Jiayi, et al.
Publicado: (2017)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer
por: Li, Shuai, et al.
Publicado: (2022)

Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2− Early Breast Cancer Patients
por: Li, Shuai, et al.
Publicado: (2022)

Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer
por: Chen, Mengdi, et al.
Publicado: (2022)

The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
por: Liu, Deyue, et al.
Publicado: (2022)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
por: Yu, Jing, et al.
Publicado: (2020)

Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample
por: Zhu, Siji, et al.
Publicado: (2019)

Reply to Letter to Editor: “HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?”
por: Li, Shuai, et al.
Publicado: (2020)

Presence of CHD1L Over-Expression Is Associated with Aggressive Tumor Biology and Is a Novel Prognostic Biomarker for Patient Survival in Human Breast Cancer
por: Wu, Jiayi, et al.
Publicado: (2014)

Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis
por: Hong, Jin, et al.
Publicado: (2020)

Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2021)

Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer
por: Gao, Weiqi, et al.
Publicado: (2019)

Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study
por: Hong, Jin, et al.
Publicado: (2016)

Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast Cancer Risk in Chinese Women
por: Zhu, Yifei, et al.
Publicado: (2020)

Associations Between Circulating Insulin-Like Growth Factor 1 and Mortality in Women With Invasive Breast Cancer
por: Zhu, Yifei, et al.
Publicado: (2020)

Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study
por: Huang, Jiahui, et al.
Publicado: (2019)

Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy
por: Huang, Renhong, et al.
Publicado: (2023)

Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma
por: Chong, Qing-Yun, et al.
Publicado: (2017)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment
por: Zhu, Siji, et al.
Publicado: (2021)

Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era
por: Liang, Yue, et al.
Publicado: (2019)

Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
por: Chen, Xiaosong, et al.
Publicado: (2015)

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2020)

A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
por: Maadi, Hamid, et al.
Publicado: (2018)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hocd1iirg7do2ms6vj5i2ho767